M&A Deal Summary

Ligand Pharmaceuticals Acquires Neurogen

On August 24, 2009, Ligand Pharmaceuticals acquired life science company Neurogen

Acquisition Highlights
  • This is Ligand Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Ligand Pharmaceuticals’ 2nd transaction in the United States.
  • This is Ligand Pharmaceuticals’ 1st transaction in Connecticut.

M&A Deal Summary
Date 2009-08-24
Target Neurogen
Sector Life Science
Buyer(s) Ligand Pharmaceuticals
Deal Type Add-on Acquisition

Target

Neurogen

Branford, Connecticut, United States
Neurogen Corp. is a drug development company historically focusing on small-molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders with significant unmet medical need. Neurogen has conducted its drug development independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ligand Pharmaceuticals

Jupiter, California, United States
Category Company
Founded 1987
Sector Life Science
Employees58
Revenue 131M USD (2023)
DESCRIPTION

Ligand Pharmaceuticals is a pharmaceutical company, develops products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand Pharmaceuticals was founded in 1987 and is based in Jupiter, Florida.

DEAL STATS #
Overall 2 of 16
Sector (Life Science) 2 of 15
Type (Add-on Acquisition) 2 of 13
State (Connecticut) 1 of 1
Country (United States) 2 of 14
Year (2009) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-09-24 Pharmacopeia

Cranbury, New Jersey, United States

Pharmacopeia, Inc. is a Drug Discovery identifying and developing small molecule drug candidates, with a primary focus on immunological diseases.

Buy $70M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-10-27 Metabasis Therapeutics

La Jolla, California, United States

Metabasis Therapeutics, Inc. is a biopharmaceutical company that has discovered novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases.

Buy -
Mergr

Product

Company

Legal